NASDAQ:REVB
Revelation Biosciences, Inc.
Revelation Biosciences, Inc. reported net income of −$8.9M in fiscal 2025. The diluted share count rose 4243.3%.Summary generated from Revelation Biosciences, Inc.'s SEC filings. Latest annual report filed Feb 26, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−131.4%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+4243.3%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | n/a | n/a |
| Operating income | −12 | −11 | −9 | −8 | −9 |
| Net income | −12 | −11 | −0 | −15 | −9 |
| Free cash flow | −11 | n/a | n/a | −18 | n/a |
Recent filings
- 8-KDirector or officer change
Aug 19, 2026 - 4Insider transaction report
Aug 18, 2026 - 4Insider transaction report
Aug 18, 2026 - 8-KResults of operations and financial condition
Aug 6, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 6, 2026 - 8-KEntry into a material agreement
Jul 13, 2026 - 8-KDirector or officer change
Jun 24, 2026 - 8-KOther events
Jun 1, 2026